ClinicalTrials.gg
CompletedNCT02608034Updated Feb 12, 2020

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

A Phase 1 interventional study of Itraconazole and Rifampin in Metastatic Melanoma, BRAF V600 Mutation Positive, sponsored by Genentech, Inc.. Completed at 11 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-12.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 57 studies in Melanoma by Hoffmann-La Roche — none open to participants now, 4 under way, none of them phase 3. Melanoma · Hoffmann-La Roche.

Planned enrollment
33rd of 52
32 · median 53
Started
2016
with 2 others
Phase 1
27 of 57
none open now
Registered
36th of 57
by date

Among the 57 studies in Melanoma by Hoffmann-La Roche, this one is the 33rd largest by planned enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2016, is one of 27 in phase 1, and was the 36th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 57 studies in Melanoma by Hoffmann-La Roche is open now. The open studies under Melanoma, anywhere →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 57 studies in Melanoma by Hoffmann-La Roche as a file.
02

Study summary

This is a two-part, Phase 1, open-label, multicenter, two-period, one-sequence study to investigate the effect of itraconazole and rifampin on the PK of vemurafenib following multiple 960 milligrams (mg) twice daily (BID) dosing in adult participants with unresectable Stage IIIC or Stage IV metastatic melanoma positive for the BRAF V600 mutation, or other malignant tumor types that harbor a V600-activating mutation of BRAF where the participant has no acceptable standard treatment options.

03

Conditions studied

  • Metastatic Melanoma, BRAF V600 Mutation Positive

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with age greater than or equal to (>=) 18 years with either unresectable Stage IIIC or Stage IV melanoma positive for the BRAF V600 mutation, or other malignant tumor types that harbor a V600-activating mutation of BRAF
  • Performance Status 0 to 2
  • >=12 weeks
  • Adequate hematologic and end organ function obtained within 2 weeks prior to first dose of study drug
  • Female participants of and male participants with partners of childbearing potential must agree to always use two effective methods of including at least one method with a failure rate of \<1% per year during the course of the study and for at least 6 months after completion of study treatment
  • Negative serum pregnancy test within 7 days prior to commencement of dosing in women of childbearing potential
  • Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with vemurafenib or other BRAF inhibitor within 42 days of Study Day 1 of Period A
  • Allergy or to components of the vemurafenib formulation
  • Experimental therapy within 4 weeks prior to first dose of study drug treatment on Study Day 1 of Period A
  • Major surgical procedure or significant traumatic injury within 14 days prior to first dose of study drug treatment on Study Day 1 of Period A, or anticipation of the need for major surgery during study treatment
  • Prior anti-cancer therapy (e.g., biologic or other targeted therapy, chemotherapy) within 28 days (6 weeks for nitrosoureas or mitomycin C, and 14 days for hormonal therapy or kinase inhibitors) before the first dose of study treatment on Study Day 1 of Period A.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Part 1: Vemurafenib+Itraconazole

    Part 1: Participants will receive vemurafenib orally BID up to Day 20 (Period A) followed by vemurafenib orally BID along with itraconazole orally once in the morning from Days 21 to 40 (Period B).\\nPart 2: Participants will receive vemurafenib orally BID up to Day 20 (Period A) followed by vemurafenib orally BID along with rifampin orally once in the morning from Days 21 to 40 (Period B).

    Drug: Itraconazole · Drug: Rifampin · Drug: Vemurafenib

Interventions

  • Itraconazole will be administered as a 200 mg oral solution QD during Part 1 only for 20 consecutive days.

  • Rifampin will be administered as a 600 mg oral solution QD during Part 2 only for 20 consecutive days.

  • Vemurafenib will be administered in both Part 1 and Part 2 at a dose of 960 mg BID for at least 40 conseutive days.

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve From Time 0 to 12 Hours Postdose (AUC0-12)

    Time frame: Period A and B: Pre-morning dose on Day 18, 19, and 20 and 1, 2, 3, 4, 6, 8, and 12 hours post-morning dose on Day 20

  2. Maximum observed concentration (Cmax)

    Time frame: Period A and B: Pre-morning dose on Day 18, 19, and 20 and 1, 2, 3, 4, 6, 8, and 12 hours post-morning dose on Day 20

  3. Time to maximum concentration (Tmax)

    Time frame: Period A and B: Pre-morning dose on Day 18, 19, and 20 and 1, 2, 3, 4, 6, 8, and 12 hours post-morning dose on Day 20

Secondary outcomes

  1. Incidence of adverse events

    Time frame: 28 days after last dose of study treatment (last dose = Day 40)

07

Study locations

11 sites
  • Mary Crowley Medical Research Center
    Dallas, Texas 75230, United States
  • Rambam Health Care Campus; Oncology
    Haifa, 3109601, Israel
  • Hadassah Ein Karem Hospital; Oncology Dept
    Jerusalem, 9112000, Israel
  • Tel Aviv Sourasky Medical Center; Pharmacy
    Tel Aviv, 64239, Israel
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Samsung Medical Center; Gastroenterology
    Seoul, 135-710, Korea, Republic of
  • Asan Medical Center; Division of Oncology
    Seoul, 138-736, Korea, Republic of
  • Severance Hospital - Yonsei Uni ; Obstetrics & Gynaecology Dept.
    Seoul, Korea, Republic of
  • Republican Clinical Oncologic Dispensary of Republic Of Tatarstan
    Kazan, 420029, Russian Federation
  • FSBSI "N. N. Blokhin Russian Cancer Research Center"
    Moscow, 115478, Russian Federation
  • St. Petersburg Oncology Hospital
    St Petersburg, 198255, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Sep 2018, 27 months.

Of 225 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 27 months is below that.

Counting every sponsor, half of 411 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2015
First posted
Nov 18, 2015
StartActual
May 26, 2016
Primary completionActual
Sep 10, 2018
CompletionActual
Sep 10, 2018
Last update
Feb 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02608034
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Nov 18, 2015
Start date
May 26, 2016
Primary completion
Sep 10, 2018
Completion
Sep 10, 2018
Last update
Feb 12, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Itraconazole · Rifampin · Vemurafenib

Start the discussion